The role of the VEGF-C/VEGFRs axis in tumor progression and therapy

International Journal of Molecular Sciences

Volumn 14, Issue 1, 2013, Pages 88-107

  Chen, Jui Chieh ^a   Chang, Yi Wen ^b   Hong, Chih Chen ^a   Yu, Yang Hao ^c   Su, Jen Liang ^a,c,d  

^a CHINA MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d ASIA UNIVERSITY   (Taiwan)

Author keywords

Angiogenesis; Lymphangiogenesis; Metastasis; VEGF C; VEGFR 2; VEGFR 3

Indexed keywords

CEDIRANIB; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; CYCLOOXYGENASE 2; HYBRID PROTEIN; IMMUNOGLOBULIN G FUSION PROTEIN; LENVATINIB; MITOGEN ACTIVATED PROTEIN KINASE P38; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 3 FC FUSION PROTEIN; SUNITINIB; UNCLASSIFIED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN C; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER PROGNOSIS; COLORECTAL CANCER; DIMERIZATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; GENE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; LEUKEMIA CELL; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR C GENE; ANIMAL; DISEASE COURSE; GENETICS; METABOLISM; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; SIGNAL TRANSDUCTION; VASCULARIZATION;

ANIMALS; DISEASE PROGRESSION; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR C;

EID: 84872202894     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14010088     Document Type: Review

References (131)

1. Senger, D.R.; Galli, S.J.; Dvorak, A.M.; Perruzzi, C.A.; Harvey, V.S.; Dvorak, H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983-985.
2. Ferrara, N.; Henzel, W.J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 161, 851-858.
3. Veikkola, T.; Karkkainen, M.; Claesson-Welsh, L.; Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60, 203-212.
4. Lohela, M.; Bry, M.; Tammela, T.; Alitalo, K. Vegfs and receptors involved in angiogenesis versus lymphangiogenesis. Curr. Opin. Cell Biol. 2009, 21, 154-165.
5. Roy, H.; Bhardwaj, S.; Yla-Herttuala, S. Biology of vascular endothelial growth factors. FEBS Lett. 2006, 580, 2879-2887.
6. Roskoski, R., Jr. Vascular endothelial growth factor (vegf) signaling in tumor progression. Crit. Rev. Oncol. Hematol. 2007, 62, 179-213.
7. Ogawa, S.; Oku, A.; Sawano, A.; Yamaguchi, S.; Yazaki, Y.; Shibuya, M. A novel type of vascular endothelial growth factor, vegf-e (nz-7 vegf), preferentially utilizes kdr/flk-1 receptor and carries a potent mitotic activity without heparin-binding domain. J. Biol. Chem. 1998, 273, 31273-31282.
8. Yamazaki, Y.; Matsunaga, Y.; Tokunaga, Y.; Obayashi, S.; Saito, M.; Morita, T. Snake venom vascular endothelial growth factors (vegf-fs) exclusively vary their structures and functions among species. J. Biol. Chem. 2009, 284, 9885-9891.
9. Kukk, E.; Lymboussaki, A.; Taira, S.; Kaipainen, A.; Jeltsch, M.; Joukov, V.; Alitalo, K. Vegf-c receptor binding and pattern of expression with vegfr-3 suggests a role in lymphatic vascular development. Development 1996, 122, 3829-3837.
10. Karkkainen, M.J.; Haiko, P.; Sainio, K.; Partanen, J.; Taipale, J.; Petrova, T.V.; Jeltsch, M.; Jackson, D.G.; Talikka, M.; Rauvala, H.; et al. Vascular endothelial growth factor c is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 2004, 5, 74-80.
11. Gore, A.V.; Swift, M.R.; Cha, Y.R.; Lo, B.; McKinney, M.C.; Li, W.; Castranova, D.; Davis, A.; Mukouyama, Y.S.; Weinstein, B.M. Rspo1/wnt signaling promotes angiogenesis via vegfc/vegfr3. Development 2011, 138, 4875-4886.
12. Hirakawa, S.; Brown, L.F.; Kodama, S.; Paavonen, K.; Alitalo, K.; Detmar, M. Vegf-c-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Blood 2007, 109, 1010-1017.
13. Cao, Y.; Linden, P.; Farnebo, J.; Cao, R.; Eriksson, A.; Kumar, V.; Qi, J.H.; Claesson-Welsh, L.; Alitalo, K. Vascular endothelial growth factor c induces angiogenesis in vivo. Proc. Natl. Acad. Sci. USA 1998, 95, 14389-14394.
14. Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E.; Saksela, O.; Kalkkinen, N.; Alitalo, K. A novel vascular endothelial growth factor, vegf-c, is a ligand for the flt4 (vegfr-3) and kdr (vegfr-2) receptor tyrosine kinases. EMBO J. 1996, 15, 290-298.
15. Paavonen, K.; Horelli-Kuitunen, N.; Chilov, D.; Kukk, E.; Pennanen, S.; Kallioniemi, O.P.; Pajusola, K.; Olofsson, B.; Eriksson, U.; Joukov, V.; et al. Novel human vascular endothelial growth factor genes vegf-b and vegf-c localize to chromosomes 11q13 and 4q34, respectively. Circulation 1996, 93, 1079-1082.
16. Fitz, L.J.; Morris, J.C.; Towler, P.; Long, A.; Burgess, P.; Greco, R.; Wang, J.; Gassaway, R.; Nickbarg, E.; Kovacic, S.; et al. Characterization of murine flt4 ligand/vegf-c. Oncogene 1997, 15, 613-618.
17. Chilov, D.; Kukk, E.; Taira, S.; Jeltsch, M.; Kaukonen, J.; Palotie, A.; Joukov, V.; Alitalo, K. Genomic organization of human and mouse genes for vascular endothelial growth factor c. J. Biol. Chem. 1997, 272, 25176-25183.
18. Li, X.; Eriksson, U. Novel vegf family members: Vegf-b, vegf-c and vegf-d. Int. J. Biochem. Cell Biol. 2001, 33, 421-426.
19. Joukov, V.; Sorsa, T.; Kumar, V.; Jeltsch, M.; Claesson-Welsh, L.; Cao, Y.; Saksela, O.; Kalkkinen, N.; Alitalo, K. Proteolytic processing regulates receptor specificity and activity of vegf-c. EMBO J. 1997, 16, 3898-3911.
20. Leppanen, V.M.; Prota, A.E.; Jeltsch, M.; Anisimov, A.; Kalkkinen, N.; Strandin, T.; Lankinen, H.; Goldman, A.; Ballmer-Hofer, K.; Alitalo, K. Structural determinants of growth factor binding and specificity by vegf receptor 2. Proc. Natl. Acad. Sci. USA 2010, 107, 2425-2430.
21. Joukov, V.; Kumar, V.; Sorsa, T.; Arighi, E.; Weich, H.; Saksela, O.; Alitalo, K. A recombinant mutant vascular endothelial growth factor-c that has lost vascular endothelial growth factor receptor-2 binding, activation, and vascular permeability activities. J. Biol. Chem. 1998, 273, 6599-6602.
22. Jeltsch, M.; Karpanen, T.; Strandin, T.; Aho, K.; Lankinen, H.; Alitalo, K. Vascular endothelial growth factor (vegf)/vegf-c mosaic molecules reveal specificity determinants and feature novel receptor binding patterns. J. Biol. Chem. 2006, 281, 12187-12195.
23. Kluger, M.S.; Colegio, O.R. Lymphangiogenesis linked to vegf-c from tumor-associated macrophages: Accomplices to metastasis by cutaneous squamous cell carcinoma? J. Invest. Dermatol. 2011, 131, 17-19.
24. Ji, R.C. Macrophages are important mediators of either tumor-or inflammation-induced lymphangiogenesis. Cell. Mol. Life Sci. 2012, 69, 897-914.
25. Skobe, M.; Hawighorst, T.; Jackson, D.G.; Prevo, R.; Janes, L.; Velasco, P.; Riccardi, L.; Alitalo, K.; Claffey, K.; Detmar, M. Induction of tumor lymphangiogenesis by vegf-c promotes breast cancer metastasis. Nat. Med. 2001, 7, 192-198.
26. Mattila, M.M.; Ruohola, J.K.; Karpanen, T.; Jackson, D.G.; Alitalo, K.; Harkonen, P.L. Vegf-c induced lymphangiogenesis is associated with lymph node metastasis in orthotopic mcf-7 tumors. Int. J. Cancer 2002, 98, 946-951.
27. Mandriota, S.J.; Jussila, L.; Jeltsch, M.; Compagni, A.; Baetens, D.; Prevo, R.; Banerji, S.; Huarte, J.; Montesano, R.; Jackson, D.G.; et al. Vascular endothelial growth factor-c-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001, 20, 672-682.
28. Laakkonen, P.; Waltari, M.; Holopainen, T.; Takahashi, T.; Pytowski, B.; Steiner, P.; Hicklin, D.; Persaud, K.; Tonra, J.R.; Witte, L.; et al. Vascular endothelial growth factor receptor 3 is involved in tumor angiogenesis and growth. Cancer Res. 2007, 67, 593-599.
29. Chien, M.H.; Ku, C.C.; Johansson, G.; Chen, M.W.; Hsiao, M.; Su, J.L.; Inoue, H.; Hua, K.T.; Wei, L.H.; Kuo, M.L. Vascular endothelial growth factor-c (vegf-c) promotes angiogenesis by induction of cox-2 in leukemic cells via the vegf-r3/jnk/ap-1 pathway. Carcinogenesis 2009, 30, 2005-2013.
30. Miettinen, M.; Rikala, M.S.; Rys, J.; Lasota, J.; Wang, Z.F. Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: An immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am. J. Surg. Pathol. 2012, 36, 629-639.
31. Su, J.L.; Yang, P.C.; Shih, J.Y.; Yang, C.Y.; Wei, L.H.; Hsieh, C.Y.; Chou, C.H.; Jeng, Y.M.; Wang, M.Y.; Chang, K.J.; et al. The vegf-c/flt-4 axis promotes invasion and metastasis of cancer cells. Cancer Cell 2006, 9, 209-223.
32. Su, J.L.; Chen, P.S.; Chien, M.H.; Chen, P.B.; Chen, Y.H.; Lai, C.C.; Hung, M.C.; Kuo, M.L. Further evidence for expression and function of the vegf-c/vegfr-3 axis in cancer cells. Cancer Cell 2008, 13, 557-560.
33. Koch, S.; Tugues, S.; Li, X.; Gualandi, L.; Claesson-Welsh, L. Signal transduction by vascular endothelial growth factor receptors. Biochem. J. 2011, 437, 169-183.
34. Dixelius, J.; Makinen, T.; Wirzenius, M.; Karkkainen, M.J.; Wernstedt, C.; Alitalo, K.; Claesson-Welsh, L. Ligand-induced vascular endothelial growth factor receptor-3 (vegfr-3) heterodimerization with vegfr-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites. J. Biol. Chem. 2003, 278, 40973-40979.
35. Nilsson, I.; Bahram, F.; Li, X.; Gualandi, L.; Koch, S.; Jarvius, M.; Soderberg, O.; Anisimov, A.; Kholova, I.; Pytowski, B.; et al. Vegf receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J. 2010, 29, 1377-1388.
36. Dosch, D.D.; Ballmer-Hofer, K. Transmembrane domain-mediated orientation of receptor monomers in active vegfr-2 dimers. FASEB J. 2010, 24, 32-38.
37. Goldman, J.; Rutkowski, J.M.; Shields, J.D.; Pasquier, M.C.; Cui, Y.; Schmokel, H.G.; Willey, S.; Hicklin, D.J.; Pytowski, B.; Swartz, M.A. Cooperative and redundant roles of vegfr-2 and vegfr-3 signaling in adult lymphangiogenesis. FASEB J. 2007, 21, 1003-1012.
38. Tvorogov, D.; Anisimov, A.; Zheng, W.; Leppanen, V.M.; Tammela, T.; Laurinavicius, S.; Holnthoner, W.; Helotera, H.; Holopainen, T.; Jeltsch, M.; et al. Effective suppression of vascular network formation by combination of antibodies blocking vegfr ligand binding and receptor dimerization. Cancer Cell 2010, 18, 630-640.
39. Feng, Y.; Hu, J.; Ma, J.; Feng, K.; Zhang, X.; Yang, S.; Wang, W.; Zhang, J.; Zhang, Y. Rnai-mediated silencing of vegf-c inhibits non-small cell lung cancer progression by simultaneously down-regulating the cxcr4, ccr7, vegfr-2 and vegfr-3-dependent axes-induced erk, p38 and akt signalling pathways. Eur. J. Cancer 2011, 47, 2353-2363.
40. Jeltsch, M.; Kaipainen, A.; Joukov, V.; Meng, X.; Lakso, M.; Rauvala, H.; Swartz, M.; Fukumura, D.; Jain, R.K.; Alitalo, K. Hyperplasia of lymphatic vessels in vegf-c transgenic mice. Science 1997, 276, 1423-1425.
41. Makinen, T.; Jussila, L.; Veikkola, T.; Karpanen, T.; Kettunen, M.I.; Pulkkanen, K.J.; Kauppinen, R.; Jackson, D.G.; Kubo, H.; Nishikawa, S.; et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble vegf receptor-3. Nat. Med. 2001, 7, 199-205.
42. Tammela, T.; Alitalo, K. Lymphangiogenesis: Molecular mechanisms and future promise. Cell 2010, 140, 460-476.
43. Khromova, N.; Kopnin, P.; Rybko, V.; Kopnin, B.P. Downregulation of vegf-c expression in lung and colon cancer cells decelerates tumor growth and inhibits metastasis via multiple mechanisms. Oncogene 2012, 31, 1389-1397.
44. Hoshida, T.; Isaka, N.; Hagendoorn, J.; di Tomaso, E.; Chen, Y.L.; Pytowski, B.; Fukumura, D.; Padera, T.P.; Jain, R.K. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-c increases metastasis by increasing delivery of cancer cells to lymph nodes: Therapeutic implications. Cancer Res. 2006, 66, 8065-8075.
45. Witzenbichler, B.; Asahara, T.; Murohara, T.; Silver, M.; Spyridopoulos, I.; Magner, M.; Principe, N.; Kearney, M.; Hu, J.S.; Isner, J.M. Vascular endothelial growth factor-c (vegf-c/vegf-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 1998, 153, 381-394.
46. Dumont, D.J.; Jussila, L.; Taipale, J.; Lymboussaki, A.; Mustonen, T.; Pajusola, K.; Breitman, M.; Alitalo, K. Cardiovascular failure in mouse embryos deficient in vegf receptor-3. Science 1998, 282, 946-949.
47. Ober, E.A.; Olofsson, B.; Makinen, T.; Jin, S.W.; Shoji, W.; Koh, G.Y.; Alitalo, K.; Stainier, D.Y. Vegfc is required for vascular development and endoderm morphogenesis in zebrafish. EMBO Rep. 2004, 5, 78-84.
48. Valtola, R.; Salven, P.; Heikkila, P.; Taipale, J.; Joensuu, H.; Rehn, M.; Pihlajaniemi, T.; Weich, H.; deWaal, R.; Alitalo, K. Vegfr-3 and its ligand vegf-c are associated with angiogenesis in breast cancer. Am. J. Pathol. 1999, 154, 1381-1390.
49. Tammela, T.; Zarkada, G.; Wallgard, E.; Murtomaki, A.; Suchting, S.; Wirzenius, M.; Waltari, M.; Hellstrom, M.; Schomber, T.; Peltonen, R.; et al. Blocking vegfr-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454, 656-660.
50. Kumar, B.; Chile, S.A.; Ray, K.B.; Reddy, G.E.; Addepalli, M.K.; Kumar, A.S.; Ramana, V.; Rajagopal, V. Vegf-c differentially regulates vegf-a expression in ocular and cancer cells; promotes angiogenesis via rhoa mediated pathway. Angiogenesis 2011, 14, 371-380.
51. Shinriki, S.; Jono, H.; Ueda, M.; Ota, K.; Ota, T.; Sueyoshi, T.; Oike, Y.; Ibusuki, M.; Hiraki, A.; Nakayama, H.; et al. Interleukin-6 signalling regulates vascular endothelial growth factor-c synthesis and lymphangiogenesis in human oral squamous cell carcinoma. J. Pathol. 2011, 225, 142-150.
52. Chen, X.; Xie, Q.; Cheng, X.; Diao, X.; Cheng, Y.; Liu, J.; Xie, W.; Chen, Z.; Zhu, B. Role of interleukin-17 in lymphangiogenesis in non-small-cell lung cancer: Enhanced production of vascular endothelial growth factor c in non-small-cell lung carcinoma cells. Cancer Sci. 2010, 101, 2384-2390.
53. Huang, C.L.; Liu, D.; Ishikawa, S.; Nakashima, T.; Nakashima, N.; Yokomise, H.; Kadota, K.; Ueno, M. Wnt1 overexpression promotes tumour progression in non-small cell lung cancer. Eur. J. Cancer 2008, 44, 2680-2688.
54. Gherghe, C.M.; Duan, J.; Gong, J.; Rojas, M.; Klauber-Demore, N.; Majesky, M.; Deb, A. Wnt1 is a proangiogenic molecule, enhances human endothelial progenitor function, and increases blood flow to ischemic limbs in a hgf-dependent manner. FASEB J. 2011, 25, 1836-1843.
55. Niederleithner, H.; Heinz, M.; Tauber, S.; Bilban, M.; Pehamberger, H.; Sonderegger, S.; Knofler, M.; Bracher, A.; Berger, W.; Loewe, R.; et al. Wnt1 is anti-lymphangiogenic in a melanoma mouse model. J. Invest. Dermatol. 2012, 132, 2235-2244.
56. Xiang, L.; Xie, G.; Ou, J.; Wei, X.; Pan, F.; Liang, H. The extra domain a of fibronectin increases vegf-c expression in colorectal carcinoma involving the pi3k/akt signaling pathway. PLoS One 2012, 7, e35378.
57. Ilan, N.; Elkin, M.; Vlodavsky, I. Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis. Int. J. Biochem. Cell Biol. 2006, 38, 2018-2039.
58. Cohen-Kaplan, V.; Naroditsky, I.; Zetser, A.; Ilan, N.; Vlodavsky, I.; Doweck, I. Heparanase induces vegf c and facilitates tumor lymphangiogenesis. Int. J. Cancer J. 2008, 123, 2566-2573.
59. Oliveira-Ferrer, L.; Tilki, D.; Ziegeler, G.; Hauschild, J.; Loges, S.; Irmak, S.; Kilic, E.; Huland, H.; Friedrich, M.; Ergun, S. Dual role of carcinoembryonic antigen-related cell adhesion molecule 1 in angiogenesis and invasion of human urinary bladder cancer. Cancer Res. 2004, 64, 8932-8938.
60. Tsai, P.W.; Shiah, S.G.; Lin, M.T.; Wu, C.W.; Kuo, M.L. Up-regulation of vascular endothelial growth factor c in breast cancer cells by heregulin-beta 1. A critical role of p38/nuclear factor-kappa b signaling pathway. J. Biol. Chem. 2003, 278, 5750-5759.
61. Sapoznik, S.; Cohen, B.; Tzuman, Y.; Meir, G.; Ben-Dor, S.; Harmelin, A.; Neeman, M. Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by ledgf-induced expression of vegf-c. Cancer Res. 2009, 69, 9306-9314.
62. Wang, C.A.; Jedlicka, P.; Patrick, A.N.; Micalizzi, D.S.; Lemmer, K.C.; Deitsch, E.; Casas-Selves, M.; Harrell, J.C.; Ford, H.L. Six1 induces lymphangiogenesis and metastasis via upregulation of vegf-c in mouse models of breast cancer. J. Clin. Invest. 2012, 122, 1895-1906.
63. Hirata, H.; Hinoda, Y.; Ueno, K.; Shahryari, V.; Tabatabai, Z.L.; Dahiya, R. Microrna-1826 targets vegfc, beta-catenin (ctnnb1) and mek1 (map2k1) in human bladder cancer. Carcinogenesis 2012, 33, 41-48.
64. Kawamura, H.; Li, X.; Goishi, K.; van Meeteren, L.A.; Jakobsson, L.; Cebe-Suarez, S.; Shimizu, A.; Edholm, D.; Ballmer-Hofer, K.; Kjellen, L.; et al. Neuropilin-1 in regulation of vegf-induced activation of p38mapk and endothelial cell organization. Blood 2008, 112, 3638-3649.
65. Herzog, B.; Pellet-Many, C.; Britton, G.; Hartzoulakis, B.; Zachary, I.C. Vegf binding to nrp1 is essential for vegf stimulation of endothelial cell migration, complex formation between nrp1 and vegfr2, and signaling via fak tyr407 phosphorylation. Mol. Biol. Cell 2011, 22, 2766-2776.
66. Herzog, Y.; Kalcheim, C.; Kahane, N.; Reshef, R.; Neufeld, G. Differential expression of neuropilin-1 and neuropilin-2 in arteries and veins. Mech. Dev. 2001, 109, 115-119.
67. Staton, C.A.; Kumar, I.; Reed, M.W.; Brown, N.J. Neuropilins in physiological and pathological angiogenesis. J. Pathol. 2007, 212, 237-248.
68. Bernatchez, P.N.; Rollin, S.; Soker, S.; Sirois, M.G. Relative effects of vegf-a and vegf-c on endothelial cell proliferation, migration and paf synthesis: Role of neuropilin-1. J. Cell. Biochem. 2002, 85, 629-639.
69. Karpanen, T.; Heckman, C.A.; Keskitalo, S.; Jeltsch, M.; Ollila, H.; Neufeld, G.; Tamagnone, L.; Alitalo, K. Functional interaction of vegf-c and vegf-d with neuropilin receptors. FASEB J. 2006, 20, 1462-1472.
70. Caunt, M.; Mak, J.; Liang, W.C.; Stawicki, S.; Pan, Q.; Tong, R.K.; Kowalski, J.; Ho, C.; Reslan, H.B.; Ross, J.; et al. Blocking neuropilin-2 function inhibits tumor cell metastasis. Cancer Cell 2008, 13, 331-342.
71. Xu, Y.; Yuan, L.; Mak, J.; Pardanaud, L.; Caunt, M.; Kasman, I.; Larrivee, B.; Del Toro, R.; Suchting, S.; Medvinsky, A.; et al. Neuropilin-2 mediates vegf-c-induced lymphatic sprouting together with vegfr3. J. Cell Biol. 2010, 188, 115-130.
72. Favier, B.; Alam, A.; Barron, P.; Bonnin, J.; Laboudie, P.; Fons, P.; Mandron, M.; Herault, J.P.; Neufeld, G.; Savi, P.; et al. Neuropilin-2 interacts with vegfr-2 and vegfr-3 and promotes human endothelial cell survival and migration. Blood 2006, 108, 1243-1250.
73. Fuster, M.M.; Wang, L.; Castagnola, J.; Sikora, L.; Reddi, K.; Lee, P.H.; Radek, K.A.; Schuksz, M.; Bishop, J.R.; Gallo, R.L.; et al. Genetic alteration of endothelial heparan sulfate selectively inhibits tumor angiogenesis. J. Cell Biol. 2007, 177, 539-549.
74. Yin, X.; Truty, J.; Lawrence, R.; Johns, S.C.; Srinivasan, R.S.; Handel, T.M.; Fuster, M.M. A critical role for lymphatic endothelial heparan sulfate in lymph node metastasis. Mol. Cancer 2010, 9, 316.
75. Yin, X.; Johns, S.C.; Lawrence, R.; Xu, D.; Reddi, K.; Bishop, J.R.; Varner, J.A.; Fuster, M.M. Lymphatic endothelial heparan sulfate deficiency results in altered growth responses to vascular endothelial growth factor-c (vegf-c). J. Biol. Chem. 2011, 286, 14952-14962.
76. Ebos, J.M.; Bocci, G.; Man, S.; Thorpe, P.E.; Hicklin, D.J.; Zhou, D.; Jia, X.; Kerbel, R.S. A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. Mol. Cancer Res. 2004, 2, 315-326.
77. Albuquerque, R.J.; Hayashi, T.; Cho, W.G.; Kleinman, M.E.; Dridi, S.; Takeda, A.; Baffi, J.Z.; Yamada, K.; Kaneko, H.; Green, M.G.; et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 2009, 15, 1023-1030.
78. Pavlakovic, H.; Becker, J.; Albuquerque, R.; Wilting, J.; Ambati, J. Soluble vegfr-2: An antilymphangiogenic variant of vegf receptors. Ann. N. Y. Acad. Sci. 2010, 1207, E7-E15.
79. Ebos, J.M.; Lee, C.R.; Bogdanovic, E.; Alami, J.; van Slyke, P.; Francia, G.; Xu, P.; Mutsaers, A.J.; Dumont, D.J.; Kerbel, R.S. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008, 68, 521-529.
80. Becker, J.; Pavlakovic, H.; Ludewig, F.; Wilting, F.; Weich, H.A.; Albuquerque, R.; Ambati, J.; Wilting, J. Neuroblastoma progression correlates with downregulation of the lymphangiogenesis inhibitor svegfr-2. Clin. Cancer Res. 2010, 16, 1431-1441.
81. Kikuchi, S.; Obata, Y.; Yagyu, K.; Lin, Y.; Nakajima, T.; Kobayashi, O.; Kikuichi, M.; Ushijima, R.; Kurosawa, M.; Ueda, J. Reduced serum vascular endothelial growth factor receptor-2 (svegfr-2) and svegfr-1 levels in gastric cancer patients. Cancer Sci. 2011, 102, 866-869.
82. Fielder, W.; Graeven, U.; Ergun, S.; Verago, S.; Kilic, N.; Stockschlader, M.; Hossfeld, D.K. Expression of flt4 and its ligand vegf-c in acute myeloid leukemia. Leukemia 1997, 11, 1234-1237.
83. De Jonge, H.J.; Weidenaar, A.C.; ter Elst, A.; Boezen, H.M.; Scherpen, F.J.; Bouma-Ter Steege, J.C.; Kaspers, G.J.; Goemans, B.F.; Creutzig, U.; Zimmermann, M.; et al. Endogenous vascular endothelial growth factor-c expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia. Clin. Cancer Res. 2008, 14, 924-930.
84. De Jonge, H.J.; Valk, P.J.; Veeger, N.J.; ter Elst, A.; den Boer, M.L.; Cloos, J.; de Haas, V.; van den Heuvel-Eibrink, M.M.; Kaspers, G.J.; Zwaan, C.M.; et al. High vegfc expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia. Blood 2010, 116, 1747-1754.
85. Bunone, G.; Vigneri, P.; Mariani, L.; Buto, S.; Collini, P.; Pilotti, S.; Pierotti, M.A.; Bongarzone, I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 1999, 155, 1967-1976.
86. Yu, X.M.; Lo, C.Y.; Chan, W.F.; Lam, K.Y.; Leung, P.; Luk, J.M. Increased expression of vascular endothelial growth factor c in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin. Cancer Res. 2005, 11, 8063-8069.
87. Yu, X.M.; Lo, C.Y.; Lam, A.K.; Leung, P.; Luk, J.M. Serum vascular endothelial growth factor c correlates with lymph node metastases and high-risk tumor profiles in papillary thyroid carcinoma. Ann. Surg. 2008, 247, 483-489.
88. Kajita, T.; Ohta, Y.; Kimura, K.; Tamura, M.; Tanaka, Y.; Tsunezuka, Y.; Oda, M.; Sasaki, T.; Watanabe, G. The expression of vascular endothelial growth factor c and its receptors in non-small cell lung cancer. Bri. J. Cancer 2001, 85, 255-260.
89. Takizawa, H.; Kondo, K.; Fujino, H.; Kenzaki, K.; Miyoshi, T.; Sakiyama, S.; Tangoku, A. The balance of vegf-c and vegfr-3 mrna is a predictor of lymph node metastasis in non-small cell lung cancer. Bri. J. Cancer 2006, 95, 75-79.
90. Kadota, K.; Huang, C.L.; Liu, D.; Ueno, M.; Kushida, Y.; Haba, R.; Yokomise, H. The clinical significance of lymphangiogenesis and angiogenesis in non-small cell lung cancer patients. Eur. J. Cancer 2008, 44, 1057-1067.
91. Datta, K.; Muders, M.; Zhang, H.; Tindall, D.J. Mechanism of lymph node metastasis in prostate cancer. Future Oncol. 2010, 6, 823-836.
92. Tsurusaki, T.; Kanda, S.; Sakai, H.; Kanetake, H.; Saito, Y.; Alitalo, K.; Koji, T. Vascular endothelial growth factor-c expression in human prostatic carcinoma and its relationship to lymph node metastasis. Bri. J. Cancer 1999, 80, 309-313.
93. Li, R.; Younes, M.; Wheeler, T.M.; Scardino, P.; Ohori, M.; Frolov, A.; Ayala, G. Expression of vascular endothelial growth factor receptor-3 (vegfr-3) in human prostate. Prostate 2004, 58, 193-199.
94. Zeng, Y.; Opeskin, K.; Baldwin, M.E.; Horvath, L.G.; Achen, M.G.; Stacker, S.A.; Sutherland, R.L.; Williams, E.D. Expression of vascular endothelial growth factor receptor-3 by lymphatic endothelial cells is associated with lymph node metastasis in prostate cancer. Clin. Cancer Res. 2004, 10, 5137-5144.
95. Duff, S.E.; Li, C.; Jeziorska, M.; Kumar, S.; Saunders, M.P.; Sherlock, D.; O'Dwyer, S.T.; Jayson, G.C. Vascular endothelial growth factors c and d and lymphangiogenesis in gastrointestinal tract malignancy. Bri. J. Cancer 2003, 89, 426-430.
96. Kitadai, Y.; Amioka, T.; Haruma, K.; Tanaka, S.; Yoshihara, M.; Sumii, K.; Matsutani, N.; Yasui, W.; Chayama, K. Clinicopathological significance of vascular endothelial growth factor (vegf)-c in human esophageal squamous cell carcinomas. Int. J. Cancer 2001, 93, 662-666.
97. Mobius, C.; Freire, J.; Becker, I.; Feith, M.; Brucher, B.L.; Hennig, M.; Siewert, J.R.; Stein, H.J. Vegf-c expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J. Surg. 2007, 31, 1768-1772; discussion 1773-1764.
98. Tanaka, T.; Ishiguro, H.; Kuwabara, Y.; Kimura, M.; Mitsui, A.; Katada, T.; Shiozaki, M.; Naganawa, Y.; Fujii, Y.; Takeyama, H. Vascular endothelial growth factor c (vegf-c) in esophageal cancer correlates with lymph node metastasis and poor patient prognosis. J. Exp. Clin. Cancer Res. 2010, 29, 83.
99. Yonemura, Y.; Endo, Y.; Fujita, H.; Fushida, S.; Ninomiya, I.; Bandou, E.; Taniguchi, K.; Miwa, K.; Ohoyama, S.; Sugiyama, K.; et al. Role of vascular endothelial growth factor c expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res. 1999, 5, 1823-1829.
100. Amioka, T.; Kitadai, Y.; Tanaka, S.; Haruma, K.; Yoshihara, M.; Yasui, W.; Chayama, K. Vascular endothelial growth factor-c expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer 2002, 38, 1413-1419.
101. Gao, P.; Zhou, G.Y.; Zhang, Q.H.; Su, Z.X.; Zhang, T.G.; Xiang, L.; Wang, Y.; Zhang, S.L.; Mu, K. Lymphangiogenesis in gastric carcinoma correlates with prognosis. J. Pathol. 2009, 218, 192-200.
102. Han, F.H.; Li, H.M.; Zheng, D.H.; He, Y.L.; Zhan, W.H. The effect of the expression of vascular endothelial growth factor (vegf)-c and vegf receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur. J. Surg. Oncol. 2010, 36, 1172-1179.
103. Kodama, M.; Kitadai, Y.; Tanaka, M.; Kuwai, T.; Tanaka, S.; Oue, N.; Yasui, W.; Chayama, K. Vascular endothelial growth factor c stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Clin. Cancer Res. 2008, 14, 7205-7214.
104. Akagi, K.; Ikeda, Y.; Miyazaki, M.; Abe, T.; Kinoshita, J.; Maehara, Y.; Sugimachi, K. Vascular endothelial growth factor-c (vegf-c) expression in human colorectal cancer tissues. Br. J. Cancer 2000, 83, 887-891.
105. George, M.L.; Tutton, M.G.; Janssen, F.; Arnaout, A.; Abulafi, A.M.; Eccles, S.A.; Swift, R.I. Vegf-a, vegf-c, and vegf-d in colorectal cancer progression. Neoplasia 2001, 3, 420-427.
106. Hanrahan, V.; Currie, M.J.; Gunningham, S.P.; Morrin, H.R.; Scott, P.A.; Robinson, B.A.; Fox, S.B. The angiogenic switch for vascular endothelial growth factor (vegf)-a, vegf-b, vegf-c, and vegf-d in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol. 2003, 200, 183-194.
107. Kinoshita, J.; Kitamura, K.; Kabashima, A.; Saeki, H.; Tanaka, S.; Sugimachi, K. Clinical significance of vascular endothelial growth factor-c (vegf-c) in breast cancer. Breast Cancer Res. Treat. 2001, 66, 159-164.
108. Mohammed, R.A.; Green, A.; El-Shikh, S.; Paish, E.C.; Ellis, I.O.; Martin, S.G. Prognostic significance of vascular endothelial cell growth factors-a,-c and-d in breast cancer and their relationship with angio-and lymphangiogenesis. Bri. J. Cancer 2007, 96, 1092-1100.
109. Wu, Q.W.; She, H.Q.; Liang, J.; Huang, Y.F.; Yang, Q.M.; Yang, Q.L.; Zhang, Z.M. Expression and clinical significance of extracellular matrix protein 1 and vascular endothelial growth factor-c in lymphatic metastasis of human breast cancer. BMC Cancer 2012, 12, 47.
110. Nakamura, Y.; Yasuoka, H.; Tsujimoto, M.; Yoshidome, K.; Nakahara, M.; Nakao, K.; Nakamura, M.; Kakudo, K. Nitric oxide in breast cancer: Induction of vascular endothelial growth factor-c and correlation with metastasis and poor prognosis. Clin. Cancer Res. 2006, 12, 1201-1207.
111. Ueda, M.; Terai, Y.; Yamashita, Y.; Kumagai, K.; Ueki, K.; Yamaguchi, H.; Akise, D.; Hung, Y.C.; Ueki, M. Correlation between vascular endothelial growth factor-c expression and invasion phenotype in cervical carcinomas. Int. J. Cancer 2002, 98, 335-343.
112. Gombos, Z.; Xu, X.; Chu, C.S.; Zhang, P.J.; Acs, G. Peritumoral lymphatic vessel density and vascular endothelial growth factor c expression in early-stage squamous cell carcinoma of the uterine cervix. Clin. Cancer Res. 2005, 11, 8364-8371.
113. Yokoyama, Y.; Charnock-Jones, D.S.; Licence, D.; Yanaihara, A.; Hastings, J.M.; Holland, C.M.; Emoto, M.; Umemoto, M.; Sakamoto, T.; Sato, S.; et al. Vascular endothelial growth factor-d is an independent prognostic factor in epithelial ovarian carcinoma. Br. J. Cancer 2003, 88, 237-244.
114. Nishida, N.; Yano, H.; Komai, K.; Nishida, T.; Kamura, T.; Kojiro, M. Vascular endothelial growth factor c and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101, 1364-1374.
115. Ueda, M.; Hung, Y.C.; Terai, Y.; Kanda, K.; Kanemura, M.; Futakuchi, H.; Yamaguchi, H.; Akise, D.; Yasuda, M.; Ueki, M. Vascular endothelial growth factor-c expression and invasive phenotype in ovarian carcinomas. Clin. Cancer Res. 2005, 11, 3225-3232.
116. Miyata, Y.; Kanda, S.; Ohba, K.; Nomata, K.; Hayashida, Y.; Eguchi, J.; Hayashi, T.; Kanetake, H. Lymphangiogenesis and angiogenesis in bladder cancer: Prognostic implications and regulation by vascular endothelial growth factors-a,-c, and-d. Clin. Cancer Res. 2006, 12, 800-806.
117. Rinderknecht, M.; Villa, A.; Ballmer-Hofer, K.; Neri, D.; Detmar, M. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-c block its interaction with vegf receptor-2 and 3. PLoS One 2010, 5, e11941.
118. Roberts, N.; Kloos, B.; Cassella, M.; Podgrabinska, S.; Persaud, K.; Wu, Y.; Pytowski, B.; Skobe, M. Inhibition of vegfr-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of vegfr-2. Cancer Res. 2006, 66, 2650-2657.
119. Burton, J.B.; Priceman, S.J.; Sung, J.L.; Brakenhielm, E.; An, D.S.; Pytowski, B.; Alitalo, K.; Wu, L. Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res. 2008, 68, 7828-7837.
120. Lin, J.; Lalani, A.S.; Harding, T.C.; Gonzalez, M.; Wu, W.W.; Luan, B.; Tu, G.H.; Koprivnikar, K.; VanRoey, M.J.; He, Y.; et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble vegfr-3 decoy receptor. Cancer Res. 2005, 65, 6901-6909.
121. Zhang, D.; Li, B.; Shi, J.; Zhao, L.; Zhang, X.; Wang, C.; Hou, S.; Qian, W.; Kou, G.; Wang, H.; et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (vegf)-a and vegf-c with a receptor-immunoglobulin fusion protein. Cancer Res. 2010, 70, 2495-2503.
122. Heckman, C.A.; Holopainen, T.; Wirzenius, M.; Keskitalo, S.; Jeltsch, M.; Yla-Herttuala, S.; Wedge, S.R.; Jurgensmeier, J.M.; Alitalo, K. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Cancer Res. 2008, 68, 4754-4762.
123. Matsui, J.; Funahashi, Y.; Uenaka, T.; Watanabe, T.; Tsuruoka, A.; Asada, M. Multi-kinase inhibitor e7080 suppresses lymph node and lung metastases of human mammary breast tumor mda-mb-231 via inhibition of vascular endothelial growth factor-receptor (vegf-r) 2 and vegf-r3 kinase. Clin. Cancer Res. 2008, 14, 5459-5465.
124. Kodera, Y.; Katanasaka, Y.; Kitamura, Y.; Tsuda, H.; Nishio, K.; Tamura, T.; Koizumi, F. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Breast Cancer Res. 2011, 13, R66.
125. Pai, S.I.; Lin, Y.Y.; Macaes, B.; Meneshian, A.; Hung, C.F.; Wu, T.C. Prospects of rna interference therapy for cancer. Gene Ther. 2006, 13, 464-477.
126. Zhang, H.; Yin, Y.; Zhang, L.; Zheng, X.; Gao, D.; Chen, K.; Zhang, Y. The effects of vascular endothelial growth factor c knockdown in esophageal squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 2012, 138, 133-139.
127. Shibata, M.A.; Morimoto, J.; Shibata, E.; Otsuki, Y. Combination therapy with short interfering rna vectors against vegf-c and vegf-a suppresses lymph node and lung metastasis in a mouse immunocompetent mammary cancer model. Cancer Gene Ther. 2008, 15, 776-786.
128. Wang, F.Q.; Barfield, E.; Dutta, S.; Pua, T.; Fishman, D.A. Vegfr-2 silencing by small interference rna (sirna) suppresses lpa-induced epithelial ovarian cancer (eoc) invasion. Gynecol. Oncol. 2009, 115, 414-423.
129. Kurenova, E.V.; Hunt, D.L.; He, D.; Fu, A.D.; Massoll, N.A.; Golubovskaya, V.M.; Garces, C.A.; Cance, W.G. Vascular endothelial growth factor receptor-3 promotes breast cancer cell proliferation, motility and survival in vitro and tumor formation in vivo. Cell Cycle 2009, 8, 2266-2280.
130. Saharinen, P.; Eklund, L.; Pulkki, K.; Bono, P.; Alitalo, K. Vegf and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol. Med. 2011, 17, 347-362.
131. ClinicalTrials. Available online: http://www.clinicaltrials.gov/(accessed on 17 December 2012).